1. Relevant Extract of USPTO Examination Report
USPTO Patent Examiner(s) took cognizance of TKDL references. Extract of examination report are reproduced below:
“Claims 1-4, 6. 7, 13, 19, 20 and 28 are rejected under 35 U.S.C. 102(b) as being anticipated by Kentebhrakam (V).
Kentebhrakam teaches a therapeutic formulation comprising the expressed juice of Sphaeranthus indicus bark, leaf, flower, fruit and root. Kentebhrakam further teaches that the formulation is an immunopotentiator. Kentebhrakam further teaches that the formulation can be combined with a medicinal liquid (which reads on a pharmaceutically acceptable carrier) and that the formulation can be orally administred.
Claims 1, 3, 4, 13, 19-24 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Khanna (O, GB 2314269 A), in view of Kentebhrakam (V) and Batra et al. (P. WO 9961026 A1).
Claims 1, 3-7, 13, 19-21 and 25-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Khanna (O, GB 2314269 A), in view of Kentebhrakam (V) and Kaiden et al. (A. 5, 334,612).”
Full examination report can be referred at 20080199550.pdf
2. Outcomes of Examination Report.
As the outcome of TKDL references and other documents cited in examination report, the Examiner decided to reject the claims 1-4, 6. 7, 13, 19, 20 and 28 on 27-Nov-13. Application was abandoned on 04.06.2014.